id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2017-E-3616-0009,FDA,FDA-2017-E-3616,Letter to U.S. Patent and Trademark Office from FDA CDER,Other,Letter(s),2020-01-22T05:00:00Z,2020,1,2020-01-22T05:00:00Z,,2020-01-22T14:10:31Z,,0,0,09000064842d4651
FDA-2017-E-3616-0008,FDA,FDA-2017-E-3616,Response Letter by FDA CDER re Citizen Petition,Other,Letter(s),2019-05-06T04:00:00Z,2019,5,2019-05-06T04:00:00Z,,2019-05-06T15:30:53Z,,0,0,0900006483c37f50
FDA-2017-E-3616-0006,FDA,FDA-2017-E-3616,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2018-12-21T05:00:00Z,2018,12,2018-12-21T05:00:00Z,,2018-12-21T18:23:37Z,,0,0,09000064839c0871
FDA-2017-E-3616-0005,FDA,FDA-2017-E-3616,"Determination of Regulatory Review Period for Purposes of Patent
Extension; ABSORB GT1 BIORESORBABLE SCAFFOLD",Notice,Determinations,2018-12-21T05:00:00Z,2018,12,2018-12-21T05:00:00Z,2019-06-20T03:59:59Z,2019-03-02T02:07:21Z,2018-27678,0,0,09000064839be0db
FDA-2017-E-3616-0004,FDA,FDA-2017-E-3616,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2018-10-01T04:00:00Z,2018,10,2018-10-01T04:00:00Z,,2018-10-01T18:39:42Z,,0,0,0900006483788978
FDA-2017-E-3616-0003,FDA,FDA-2017-E-3616,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2017-08-03T04:00:00Z,2017,8,2017-08-03T04:00:00Z,,2017-08-03T14:42:13Z,,0,0,090000648299ad22
FDA-2017-E-3616-0002,FDA,FDA-2017-E-3616,Letter from U.S. Patent and Trademark Office to CDER,Other,Letter(s),2017-06-09T04:00:00Z,2017,6,2017-06-09T04:00:00Z,,2017-06-09T13:39:21Z,,0,0,09000064826b5bbc
FDA-2017-E-3616-0001,FDA,FDA-2017-E-3616,"Patent Extension Application fromSquire Patton Boggs (US) LLP (on behalf of ABBOTT CARDIOVASCULAR SYSTEMS INC. (""ABBOTT""))",Other,Application,2017-06-09T04:00:00Z,2017,6,2017-06-09T04:00:00Z,,2017-06-09T13:36:47Z,,0,0,09000064826b5af1